ONCY Is a Small Cap Nasdaq Biotech Turning up the Heat With FDA Momentum

Unsubscribe

This has been disseminated on behalf of Oncolytics Biotech

ONCY Is a Small Cap Nasdaq Biotech Turning up the Heat With FDA Momentum

Oncolytics Biotech (NASDAQ: ONCY) is starting to separate itself from a crowded biotech field thanks to pelareorep, its first-in-class dsRNA immunotherapy platform that’s producing unusually strong data in some of the hardest GI cancers to treat. 

The company recently scored a major win after aligning with the FDA on a pivotal trial design for metastatic anal cancer, putting ONCY on a clearer regulatory path moving forward. But the real headline grabber has been the colorectal cancer data. 

Pelareorep showed a 19.5-month median duration of response in KRAS-mutant MSS colorectal cancer — massively outperforming the typical 4–6 month benchmark seen with current therapies. Add in a 33% response rate and 27-month median overall survival, and investors are starting to view ONCY as more than just another early-stage biotech story.

What makes the platform especially interesting is that pelareorep appears designed to tackle the exact reason immunotherapy has historically struggled in GI cancers. Instead of relying solely on checkpoint inhibitors, pelareorep works to activate the immune system and “heat up” tumors that are normally resistant to treatment. 

With multiple Fast Track designations, over 1,200 patients treated, and billion-dollar market opportunities across colorectal, pancreatic, and anal cancers, ONCY is building a story centered around both massive unmet need and potentially game-changing durability data. 

If upcoming studies continue delivering results like these, pelareorep could emerge as one of the more disruptive immunotherapy platforms in the GI oncology space.

WITH REAL CANCER DATA AND FDA TRACTION, ONCY DESERVES A SPOT ON YOUR WATCHLIST!

 


 

 

 

 
 
  This email was sent to punjabsvera@gmail.com by editor@dailymarketalerts.com

DailyMarketAlerts c/o CLM Global Enterprises, LLC (dba CLM Media) 45 South Park Place, #203, Morristown, NJ 07960 United States

 
 

Post a Comment

Previous Post Next Post

Contact Form